1. Home
  2. IPHA vs BYRN Comparison

IPHA vs BYRN Comparison

Compare IPHA & BYRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$2.15

Market Cap

165.3M

Sector

Health Care

ML Signal

N/A

Logo Byrna Technologies Inc.

BYRN

Byrna Technologies Inc.

N/A

Current Price

$3.36

Market Cap

136.3M

Sector

Miscellaneous

ML Signal

N/A

Company Overview

Basic Information
Metric
IPHA
BYRN
Founded
1999
2005
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
165.3M
136.3M
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
IPHA
BYRN
Price
$2.15
$3.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$5.75
$23.17
AVG Volume (30 Days)
174.9K
381.5K
Earning Date
03-26-2026
04-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,566,295.00
Revenue This Year
$180.36
$4.98
Revenue Next Year
N/A
$16.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1692.08
52 Week Low
$1.18
$3.17
52 Week High
$2.71
$30.62

Technical Indicators

Market Signals
Indicator
IPHA
BYRN
Relative Strength Index (RSI) 52.48 36.10
Support Level $1.67 $3.17
Resistance Level $2.66 $5.17
Average True Range (ATR) 0.08 0.16
MACD -0.02 -0.02
Stochastic Oscillator 38.46 4.32

Price Performance

Historical Comparison
IPHA
BYRN

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

About BYRN Byrna Technologies Inc.

Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.

Share on Social Networks: